Terms: = Colorectal cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
271 results:
1. Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in colorectal Carcinoma Cells.
Jacksi M; Schad E; Tantos A
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672463
[TBL] [Abstract] [Full Text] [Related]
2. B7-H3 Expression in Breast cancer and Brain Metastasis.
Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
[TBL] [Abstract] [Full Text] [Related]
3. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Stucchi E; Bartolini M; Airoldi M; Fazio R; Daprà V; Mondello G; Prete MG; Puccini A; Santoro A
Expert Opin Pharmacother; 2024 Mar; 25(4):371-382. PubMed ID: 38568032
[TBL] [Abstract] [Full Text] [Related]
4. Circular RNA circTATDN3 promotes the Warburg effect and proliferation in colorectal cancer.
Lin J; Zhong W; Lyu Z; Peng J; Rong Y; Zeng K; Lai J; Wu D; Wang J; Li Y; Zheng J; Zhang J; Pan Z
Cancer Lett; 2024 May; 589():216825. PubMed ID: 38548218
[TBL] [Abstract] [Full Text] [Related]
5. Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling.
Chomiak AA; Tiedemann RL; Liu Y; Kong X; Cui Y; Wiseman AK; Thurlow KE; Cornett EM; Topper MJ; Baylin SB; Rothbart SB
Sci Adv; 2024 Mar; 10(13):eadk4423. PubMed ID: 38536911
[TBL] [Abstract] [Full Text] [Related]
6. Synergic actions of botulinum neurotoxin A and oxaliplatin on colorectal tumour cell death through the upregulation of TRPM2 channel-mediated oxidative stress.
Demir S; Duman İ; Nazıroğlu M
Clin Exp Pharmacol Physiol; 2024 Apr; 51(4):e13844. PubMed ID: 38350599
[TBL] [Abstract] [Full Text] [Related]
7. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.
McCarthy G; Young K; Madin-Warburton M; Mantaian T; Brook E; Metcalfe K; Mikelson J; Xu R; Seyla-Hammer C; Aguiar-Ibáñez R; Amonkar M
J Med Econ; 2024; 27(1):279-291. PubMed ID: 38293714
[TBL] [Abstract] [Full Text] [Related]
8. Soluble B7-H3 in colorectal cancer.
Kovaleva OV; Gratchev AN; Sokolov NY; Maslennikov VV; Kuzmin YB; Gershtein ES; Alferov AA; Mamedli ZZ; Stilidi IS; Kushlinskii NE
Bull Exp Biol Med; 2023 Nov; 176(1):87-90. PubMed ID: 38085395
[TBL] [Abstract] [Full Text] [Related]
9. Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges.
Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
[TBL] [Abstract] [Full Text] [Related]
10. B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention.
Varghese E; Samuel SM; Brockmueller A; Shakibaei M; Kubatka P; Büsselberg D
Cancer Metastasis Rev; 2024 Mar; 43(1):115-133. PubMed ID: 37768439
[TBL] [Abstract] [Full Text] [Related]
11. Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in colorectal cancer Cells.
Tsai FL; Huang HL; Lai MJ; Liou JP; Pan SL; Yang CR
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628767
[TBL] [Abstract] [Full Text] [Related]
12. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer.
Li W; Zhou C; Yu L; Hou Z; Liu H; Kong L; Xu Y; He J; Lan J; Ou Q; Fang Y; Lu Z; Wu X; Pan Z; Peng J; Lin J
Autophagy; 2024 Jan; 20(1):114-130. PubMed ID: 37615625
[TBL] [Abstract] [Full Text] [Related]
13. Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3.
Rampuria P; Mosyak L; Root AR; Svenson K; Agostino MJ; LaVallie ER
Sci Rep; 2023 Aug; 13(1):13408. PubMed ID: 37591971
[TBL] [Abstract] [Full Text] [Related]
14. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
[TBL] [Abstract] [Full Text] [Related]
15. ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells.
Xu H; Li P; Ma H; Tan Y; Wang X; Cai F; Xu J; Sun H; Zhuang H; Hua ZC
Cancer Med; 2023 Aug; 12(16):17193-17211. PubMed ID: 37492969
[TBL] [Abstract] [Full Text] [Related]
16. CNN2 silencing inhibits colorectal cancer development through promoting ubiquitination of EGR1.
He J; Yang X; Zhang C; Li A; Wang W; Xing J; E J; Xu X; Wang H; Yu E; Shi D; Wang H
Life Sci Alliance; 2023 Jul; 6(7):. PubMed ID: 37188478
[TBL] [Abstract] [Full Text] [Related]
17. [Two Cases of Transfusion-Free Hepatectomy Following Chemotherapy for H3 Grade of Simultaneous Liver Metastases].
Ogawa T; Kawamoto S; Yamamoto K; Atarashi M; Terashima T; Kurogi N
Gan To Kagaku Ryoho; 2023 Feb; 50(2):236-238. PubMed ID: 36807183
[TBL] [Abstract] [Full Text] [Related]
18. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
Zekri L; Lutz M; Prakash N; Manz T; Klimovich B; Mueller S; Hoerner S; Hagelstein I; Engel M; Chashchina A; Pfluegler M; Heitmann JS; Jung G; Salih HR
Mol Ther; 2023 Apr; 31(4):1033-1045. PubMed ID: 36793213
[TBL] [Abstract] [Full Text] [Related]
19. Whole-exome sequencing of rectal neuroendocrine tumors.
Li Y; Guo Y; Cheng Z; Tian C; Chen Y; Chen R; Yu F; Shi Y; Su F; Zhao S; Wang Z; Luo J; Tan H
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 36645718
[TBL] [Abstract] [Full Text] [Related]
20. Rational Design of a Triple Tumor Microenvironment-Responsive Nanoplatform for Enhanced Tumor Theranostics.
Zhang S; Han X; Chen X; Liu Y; Zhou J
Chemistry; 2023 Feb; 29(7):e202202469. PubMed ID: 36219493
[TBL] [Abstract] [Full Text] [Related]
[Next]
